Myriad Genetics, Inc. MYGN

NAS: MYGN | ISIN: US62855J1043   30/04/2025
7,410 USD (+2,92%)
(+2,92%)   30/04/2025

11 juni 2024 · Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries · Persbericht

28 september 2023 · Breast Cancer Awareness Month: New Cancer Risk Survey Reveals Risk Factors Are Widely Misunderstood · Persbericht

2 maart 2023 · Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States · Persbericht

31 augustus 2022 · New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients · Persbericht

31 augustus 2022 · Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein · Persbericht

16 augustus 2022 · Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe · Persbericht

7 september 2021 · Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations · Persbericht

27 mei 2021 · IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety · Persbericht

2 maart 2021 · Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services · Persbericht

23 februari 2021 · Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan · Persbericht

18 februari 2021 · Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives · Persbericht

16 februari 2021 · Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 · Persbericht

12 februari 2021 · New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer · Persbericht

11 februari 2021 · Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences · Persbericht

8 februari 2021 · GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels · Persbericht

2 februari 2021 · Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis · Persbericht

19 januari 2021 · Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan · Persbericht

18 januari 2021 · SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors · Persbericht

11 januari 2021 · Myriad Genetics Forms Strategic Partnership with Illumina in Oncology · Persbericht

8 januari 2021 · Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® · Persbericht

Mijn selecties